Shopping Cart 0
Cart Subtotal
AED 0

ASIA-PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 5505

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 8074

Details

MARKET OUTLOOK

The Triton Market Research report states that the Asia-Pacific hyperphosphatemia drugs market is expected to grow in terms of revenue with a CAGR of 17.86% during the forecast period 2019 to 2027.

The countries of India, China, Japan, South Korea, Australia & New Zealand, ASEAN countries and countries in rest of APAC together constitute the market for hyperphosphatemia drugs in the Asia-Pacific region.

The growth of Asia-Pacific hyperphosphatemia drugs market can majorly be attributed to the growing aging populace, increase in the cases of osteoporosis and the changing dietary habits of people. Amongst these, the high prevalence of osteoporosis is the major driver for the hyperphosphatemia drugs market in this region. Osteoporosis is significantly undertreated and underdiagnosed in this region, even in the high-risk patients who have experienced previous fractures. In Asia-Pacific's most populated countries such as India and China, hip fractures are frequently treated conventionally at their house as an alternative to surgical treatment in hospitals.

Whereas, the changing dietary habits of people have led to the hyperphosphatemia drug market growth in Australia. The increased phosphate levels in the body give rise to hyperphosphatemia. High phosphate-containing foods are meat, dairy items, fast food, soft drinks, nuts, seeds, chocolates and processed food. The consumption of these food items increases the phosphorous level in the body, eventually leading to diseases such as hyperphosphatemia. Thus, the changing dietary habits and a shift from functional foods to processed foods are mainly responsible for causing hyperphosphatemia in the region.

COMPETITIVE OUTLOOK

Top companies that have been studied in the market are Shire, Zeria Pharmaceutical, Sanofi, Royal DSM N.V., Keryx Biopharmaceuticals, Inc., Sun Pharmaceutical Industries, Ltd., Bruno Farmaceutici S.p.A., Fermenta Biotech, Ltd., Roche Diagnostics Corporation, Cipla, Bio-Tech Pharmacal, Fresenius Medical Care, Johnson and Johnson, Pfizer, Inc., AMAG Pharmaceuticals and Ultragenyx Pharmaceutical, Inc.

READ MORE

Table Of Content

Scope

TABLE OF CONTENT

1. ASIA-PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET-SUMMARY

2. INDUSTRY OUTLOOK

2.1. MARKET DEFINITION

2.2. PORTER'S FIVE FORCE MODEL

2.2.1. THREAT OF NEW ENTRANTS

2.2.2. BARGAINING POWER OF BUYERS

2.2.3. BARGAINING POWER OF SUPPLIERS

2.2.4. THREAT OF SUBSTITUTE PRODUCT

2.2.5. INTENSITY OF COMPETITIVE RIVALRY

2.3. VENDOR SCORECARD

2.4. KEY BUYING OUTLOOK

2.5. KEY INSIGHTS

2.6. KEY MARKET TRENDS

2.7. GUIDELINES RELATED TO THE PHOSPHATE BINDERS

2.8. MARKET DRIVERS

2.8.1. CHRONIC DISORDERS ARE INCREASING RAPIDLY

2.8.2. INCREASE IN PUBLIC COGNIZANCE

2.8.3. INCREASE IN GERIATRIC POPULATION

2.9. MARKET RESTRAINTS

2.9.1. SIDE-EFFECTS RELATED TO THE USAGE OF HYPERPHOSPHATEMIA DRUGS

2.9.2. STRICT FOOD AND DRUG ADMINISTRATION (FDA) REGULATIONS

2.10. MARKET OPPORTUNITIES

2.10.1. RISE IN THE AGING POPULATION

2.11. MARKET CHALLENGES

2.11.1. ALTERNATIVE DIALYSIS TECHNIQUES

2.11.2. ACCESSIBILITY OF DRUGS IS LIMITED

2.11.3. NON-ADHERENCE TO TREATMENT REGIMES

3. HYPERPHOSPHATEMIA DRUGS MARKET OUTLOOK-BY DOSAGES

3.1. SOLID

3.1.1. TABLET

3.1.2. POWDER

3.2. LIQUID

3.2.1. SOLUTION

4. HYPERPHOSPHATEMIA DRUGS MARKET OUTLOOK-BY FORMULATION

4.1.1. CALCIUM-BASED PHOSPHATE BINDERS

4.1.2. ALUMINUM-BASED PHOSPHATE BINDERS

4.1.3. MAGNESIUM-BASED PHOSPHATE BINDERS

4.1.4. IRON-BASED PHOSPHATE BINDERS

4.1.5. OTHER PHOSPHATE BINDERS

5. HYPERPHOSPHATEMIA DRUGS MARKET-REGIONAL OUTLOOK

5.1. ASIA-PACIFIC

5.1.1. COUNTRY ANALYSIS

5.1.1.1. INDIA

5.1.1.2. CHINA

5.1.1.3. JAPAN

5.1.1.4. SOUTH KOREA

5.1.1.5. ASEAN COUNTRIES

5.1.1.6. AUSTRALIA & NEW ZEALAND

5.1.1.7. REST OF APAC

6. COMPETITIVE LANDSCAPE

6.1. JOHNSON AND JOHNSON

6.2. ZERIA PHARMACEUTICAL

6.3. AMAG PHARMACEUTICALS

6.4. SANOFI

6.5. BRUNO FARMACEUTICI S.P.A.

6.6. ROCHE DIAGNOSTICS CORPORATION

6.7. ROYAL DSM N.V.

6.8. SHIRE

6.9. CIPLA

6.10. ULTRAGENYX PHARMACEUTICAL, INC.

6.11. FERMENTA BIOTECH, LTD.

6.12. BIOTECH PHARMACAL

6.13. SUN PHARMACEUTICAL INDUSTRIES, LTD.

6.14. KERYX BIOPHARMACEUTICALS, INC.

6.15. FRESENIUS MEDICAL CARE

6.16. PFIZER, INC.

7. METHODOLOGY & SCOPE

7.1. RESEARCH SCOPE

7.2. SOURCES OF DATA

7.3. RESEARCH METHODOLOGY

 

 

 

 

 

TABLES LIST

TABLE 1 ASIA-PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

TABLE 2 PHOSPHOROUS LEVELS IN SELECT FOODS

TABLE 3 ASIA-PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET BY FORMULATION 2019-2027 (USD MILLION)

TABLE 4 DIAGNOSIS AND CLINICAL INDICATORS OF CHRONIC KIDNEY DISEASE

TABLE 5 ASIA-PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET COUNTRY ANALYSIS 2019-2027 (USD MILLION)

TABLE 6 PER CAPITA CONSUMPTION OF DAIRY PRODUCTS IN AUSTRALIA

 

 

FIGURES LIST

FIGURE 1 PORTER'S FIVE FORCE MODEL OF HYPERPHOSPHATEMIA DRUGS MARKET

FIGURE 2 IRON-BASED HYPERPHOSPHATEMIA DRUG APPROVAL STATUS 2014-2017

FIGURE 3 RATE OF ADHERENCE TO PHOSPHATE BINDERS

FIGURE 4 ASIA-PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET IN CALCIUM-BASED PHOSPHATE BINDERS 2019-2027 (USD MILLION)

FIGURE 5 ASIA-PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET IN ALUMINUM-BASED PHOSPHATE BINDERS 2019-2027 (USD MILLION)

FIGURE 6 ASIA-PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET IN MAGNESIUM-BASED PHOSPHATE BINDERS 2019-2027 (USD MILLION)

FIGURE 7 ASIA-PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET IN IRON-BASED PHOSPHATE BINDERS 2019-2027 (USD MILLION)

FIGURE 8 ASIA-PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET IN OTHER PHOSPHATE BINDERS 2019-2027 (USD MILLION)

FIGURE 9 ASIA-PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET SHARE 2018 & 2027 (%)

FIGURE 10 ASIA-PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

FIGURE 11 AGEWISE DISTRIBUTION OF ELDERLY POPULATION IN INDIA

FIGURE 12 INDIA HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

FIGURE 13 CHINA HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

FIGURE 14 JAPAN HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

FIGURE 15 NUMBER OF FRACTURES DUE TO OSTEOPOROSIS AND OSTEOPENIA

FIGURE 16 SOUTH KOREA HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

FIGURE 17 ASEAN COUNTRIESHYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

FIGURE 18 AUSTRALIA & NEW ZEALAND HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

FIGURE 19 ROAPAC HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)


List Of Figure

FIGURES LIST

FIGURE 1 PORTER'S FIVE FORCE MODEL OF HYPERPHOSPHATEMIA DRUGS MARKET

FIGURE 2 IRON-BASED HYPERPHOSPHATEMIA DRUG APPROVAL STATUS 2014-2017

FIGURE 3 RATE OF ADHERENCE TO PHOSPHATE BINDERS

FIGURE 4 ASIA-PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET IN CALCIUM-BASED PHOSPHATE BINDERS 2019-2027 (USD MILLION)

FIGURE 5 ASIA-PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET IN ALUMINUM-BASED PHOSPHATE BINDERS 2019-2027 (USD MILLION)

FIGURE 6 ASIA-PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET IN MAGNESIUM-BASED PHOSPHATE BINDERS 2019-2027 (USD MILLION)

FIGURE 7 ASIA-PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET IN IRON-BASED PHOSPHATE BINDERS 2019-2027 (USD MILLION)

FIGURE 8 ASIA-PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET IN OTHER PHOSPHATE BINDERS 2019-2027 (USD MILLION)

FIGURE 9 ASIA-PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET SHARE 2018 & 2027 (%)

FIGURE 10 ASIA-PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

FIGURE 11 AGEWISE DISTRIBUTION OF ELDERLY POPULATION IN INDIA

FIGURE 12 INDIA HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

FIGURE 13 CHINA HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

FIGURE 14 JAPAN HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

FIGURE 15 NUMBER OF FRACTURES DUE TO OSTEOPOROSIS AND OSTEOPENIA

FIGURE 16 SOUTH KOREA HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

FIGURE 17 ASEAN COUNTRIESHYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

FIGURE 18 AUSTRALIA & NEW ZEALAND HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

FIGURE 19 ROAPAC HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)


List Of Table

TABLES LIST

TABLE 1 ASIA-PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

TABLE 2 PHOSPHOROUS LEVELS IN SELECT FOODS

TABLE 3 ASIA-PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET BY FORMULATION 2019-2027 (USD MILLION)

TABLE 4 DIAGNOSIS AND CLINICAL INDICATORS OF CHRONIC KIDNEY DISEASE

TABLE 5 ASIA-PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET COUNTRY ANALYSIS 2019-2027 (USD MILLION)

TABLE 6 PER CAPITA CONSUMPTION OF DAIRY PRODUCTS IN AUSTRALIA

Licence Rights

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies


Companies

1. JOHNSON AND JOHNSON

2. ZERIA PHARMACEUTICAL

3. AMAG PHARMACEUTICALS

4. SANOFI

5. BRUNO FARMACEUTICI S.P.A.

6. ROCHE DIAGNOSTICS CORPORATION

7. ROYAL DSM N.V.

8. SHIRE

9. CIPLA

10. ULTRAGENYX PHARMACEUTICAL, INC.

11. FERMENTA BIOTECH, LTD.

12. BIOTECH PHARMACAL

13. SUN PHARMACEUTICAL INDUSTRIES, LTD.

14. KERYX BIOPHARMACEUTICALS, INC.

15. FRESENIUS MEDICAL CARE

16. PFIZER, INC.

Company Profile

Company Profile Title

MARKET OUTLOOK

The Triton Market Research report states that the Asia-Pacific hyperphosphatemia drugs market is expected to grow in terms of revenue with a CAGR of 17.86% during the forecast period 2019 to 2027.

The countries of India, China, Japan, South Korea, Australia & New Zealand, ASEAN countries and countries in rest of APAC together constitute the market for hyperphosphatemia drugs in the Asia-Pacific region.

The growth of Asia-Pacific hyperphosphatemia drugs market can majorly be attributed to the growing aging populace, increase in the cases of osteoporosis and the changing dietary habits of people. Amongst these, the high prevalence of osteoporosis is the major driver for the hyperphosphatemia drugs market in this region. Osteoporosis is significantly undertreated and underdiagnosed in this region, even in the high-risk patients who have experienced previous fractures. In Asia-Pacific's most populated countries such as India and China, hip fractures are frequently treated conventionally at their house as an alternative to surgical treatment in hospitals.

Whereas, the changing dietary habits of people have led to the hyperphosphatemia drug market growth in Australia. The increased phosphate levels in the body give rise to hyperphosphatemia. High phosphate-containing foods are meat, dairy items, fast food, soft drinks, nuts, seeds, chocolates and processed food. The consumption of these food items increases the phosphorous level in the body, eventually leading to diseases such as hyperphosphatemia. Thus, the changing dietary habits and a shift from functional foods to processed foods are mainly responsible for causing hyperphosphatemia in the region.

COMPETITIVE OUTLOOK

Top companies that have been studied in the market are Shire, Zeria Pharmaceutical, Sanofi, Royal DSM N.V., Keryx Biopharmaceuticals, Inc., Sun Pharmaceutical Industries, Ltd., Bruno Farmaceutici S.p.A., Fermenta Biotech, Ltd., Roche Diagnostics Corporation, Cipla, Bio-Tech Pharmacal, Fresenius Medical Care, Johnson and Johnson, Pfizer, Inc., AMAG Pharmaceuticals and Ultragenyx Pharmaceutical, Inc.

READ MORE

Scope

TABLE OF CONTENT

1. ASIA-PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET-SUMMARY

2. INDUSTRY OUTLOOK

2.1. MARKET DEFINITION

2.2. PORTER'S FIVE FORCE MODEL

2.2.1. THREAT OF NEW ENTRANTS

2.2.2. BARGAINING POWER OF BUYERS

2.2.3. BARGAINING POWER OF SUPPLIERS

2.2.4. THREAT OF SUBSTITUTE PRODUCT

2.2.5. INTENSITY OF COMPETITIVE RIVALRY

2.3. VENDOR SCORECARD

2.4. KEY BUYING OUTLOOK

2.5. KEY INSIGHTS

2.6. KEY MARKET TRENDS

2.7. GUIDELINES RELATED TO THE PHOSPHATE BINDERS

2.8. MARKET DRIVERS

2.8.1. CHRONIC DISORDERS ARE INCREASING RAPIDLY

2.8.2. INCREASE IN PUBLIC COGNIZANCE

2.8.3. INCREASE IN GERIATRIC POPULATION

2.9. MARKET RESTRAINTS

2.9.1. SIDE-EFFECTS RELATED TO THE USAGE OF HYPERPHOSPHATEMIA DRUGS

2.9.2. STRICT FOOD AND DRUG ADMINISTRATION (FDA) REGULATIONS

2.10. MARKET OPPORTUNITIES

2.10.1. RISE IN THE AGING POPULATION

2.11. MARKET CHALLENGES

2.11.1. ALTERNATIVE DIALYSIS TECHNIQUES

2.11.2. ACCESSIBILITY OF DRUGS IS LIMITED

2.11.3. NON-ADHERENCE TO TREATMENT REGIMES

3. HYPERPHOSPHATEMIA DRUGS MARKET OUTLOOK-BY DOSAGES

3.1. SOLID

3.1.1. TABLET

3.1.2. POWDER

3.2. LIQUID

3.2.1. SOLUTION

4. HYPERPHOSPHATEMIA DRUGS MARKET OUTLOOK-BY FORMULATION

4.1.1. CALCIUM-BASED PHOSPHATE BINDERS

4.1.2. ALUMINUM-BASED PHOSPHATE BINDERS

4.1.3. MAGNESIUM-BASED PHOSPHATE BINDERS

4.1.4. IRON-BASED PHOSPHATE BINDERS

4.1.5. OTHER PHOSPHATE BINDERS

5. HYPERPHOSPHATEMIA DRUGS MARKET-REGIONAL OUTLOOK

5.1. ASIA-PACIFIC

5.1.1. COUNTRY ANALYSIS

5.1.1.1. INDIA

5.1.1.2. CHINA

5.1.1.3. JAPAN

5.1.1.4. SOUTH KOREA

5.1.1.5. ASEAN COUNTRIES

5.1.1.6. AUSTRALIA & NEW ZEALAND

5.1.1.7. REST OF APAC

6. COMPETITIVE LANDSCAPE

6.1. JOHNSON AND JOHNSON

6.2. ZERIA PHARMACEUTICAL

6.3. AMAG PHARMACEUTICALS

6.4. SANOFI

6.5. BRUNO FARMACEUTICI S.P.A.

6.6. ROCHE DIAGNOSTICS CORPORATION

6.7. ROYAL DSM N.V.

6.8. SHIRE

6.9. CIPLA

6.10. ULTRAGENYX PHARMACEUTICAL, INC.

6.11. FERMENTA BIOTECH, LTD.

6.12. BIOTECH PHARMACAL

6.13. SUN PHARMACEUTICAL INDUSTRIES, LTD.

6.14. KERYX BIOPHARMACEUTICALS, INC.

6.15. FRESENIUS MEDICAL CARE

6.16. PFIZER, INC.

7. METHODOLOGY & SCOPE

7.1. RESEARCH SCOPE

7.2. SOURCES OF DATA

7.3. RESEARCH METHODOLOGY

 

 

 

 

 

TABLES LIST

TABLE 1 ASIA-PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

TABLE 2 PHOSPHOROUS LEVELS IN SELECT FOODS

TABLE 3 ASIA-PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET BY FORMULATION 2019-2027 (USD MILLION)

TABLE 4 DIAGNOSIS AND CLINICAL INDICATORS OF CHRONIC KIDNEY DISEASE

TABLE 5 ASIA-PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET COUNTRY ANALYSIS 2019-2027 (USD MILLION)

TABLE 6 PER CAPITA CONSUMPTION OF DAIRY PRODUCTS IN AUSTRALIA

 

 

FIGURES LIST

FIGURE 1 PORTER'S FIVE FORCE MODEL OF HYPERPHOSPHATEMIA DRUGS MARKET

FIGURE 2 IRON-BASED HYPERPHOSPHATEMIA DRUG APPROVAL STATUS 2014-2017

FIGURE 3 RATE OF ADHERENCE TO PHOSPHATE BINDERS

FIGURE 4 ASIA-PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET IN CALCIUM-BASED PHOSPHATE BINDERS 2019-2027 (USD MILLION)

FIGURE 5 ASIA-PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET IN ALUMINUM-BASED PHOSPHATE BINDERS 2019-2027 (USD MILLION)

FIGURE 6 ASIA-PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET IN MAGNESIUM-BASED PHOSPHATE BINDERS 2019-2027 (USD MILLION)

FIGURE 7 ASIA-PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET IN IRON-BASED PHOSPHATE BINDERS 2019-2027 (USD MILLION)

FIGURE 8 ASIA-PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET IN OTHER PHOSPHATE BINDERS 2019-2027 (USD MILLION)

FIGURE 9 ASIA-PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET SHARE 2018 & 2027 (%)

FIGURE 10 ASIA-PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

FIGURE 11 AGEWISE DISTRIBUTION OF ELDERLY POPULATION IN INDIA

FIGURE 12 INDIA HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

FIGURE 13 CHINA HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

FIGURE 14 JAPAN HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

FIGURE 15 NUMBER OF FRACTURES DUE TO OSTEOPOROSIS AND OSTEOPENIA

FIGURE 16 SOUTH KOREA HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

FIGURE 17 ASEAN COUNTRIESHYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

FIGURE 18 AUSTRALIA & NEW ZEALAND HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

FIGURE 19 ROAPAC HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)


List Of Figure

FIGURES LIST

FIGURE 1 PORTER'S FIVE FORCE MODEL OF HYPERPHOSPHATEMIA DRUGS MARKET

FIGURE 2 IRON-BASED HYPERPHOSPHATEMIA DRUG APPROVAL STATUS 2014-2017

FIGURE 3 RATE OF ADHERENCE TO PHOSPHATE BINDERS

FIGURE 4 ASIA-PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET IN CALCIUM-BASED PHOSPHATE BINDERS 2019-2027 (USD MILLION)

FIGURE 5 ASIA-PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET IN ALUMINUM-BASED PHOSPHATE BINDERS 2019-2027 (USD MILLION)

FIGURE 6 ASIA-PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET IN MAGNESIUM-BASED PHOSPHATE BINDERS 2019-2027 (USD MILLION)

FIGURE 7 ASIA-PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET IN IRON-BASED PHOSPHATE BINDERS 2019-2027 (USD MILLION)

FIGURE 8 ASIA-PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET IN OTHER PHOSPHATE BINDERS 2019-2027 (USD MILLION)

FIGURE 9 ASIA-PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET SHARE 2018 & 2027 (%)

FIGURE 10 ASIA-PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

FIGURE 11 AGEWISE DISTRIBUTION OF ELDERLY POPULATION IN INDIA

FIGURE 12 INDIA HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

FIGURE 13 CHINA HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

FIGURE 14 JAPAN HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

FIGURE 15 NUMBER OF FRACTURES DUE TO OSTEOPOROSIS AND OSTEOPENIA

FIGURE 16 SOUTH KOREA HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

FIGURE 17 ASEAN COUNTRIESHYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

FIGURE 18 AUSTRALIA & NEW ZEALAND HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

FIGURE 19 ROAPAC HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)


List Of Table

TABLES LIST

TABLE 1 ASIA-PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

TABLE 2 PHOSPHOROUS LEVELS IN SELECT FOODS

TABLE 3 ASIA-PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET BY FORMULATION 2019-2027 (USD MILLION)

TABLE 4 DIAGNOSIS AND CLINICAL INDICATORS OF CHRONIC KIDNEY DISEASE

TABLE 5 ASIA-PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET COUNTRY ANALYSIS 2019-2027 (USD MILLION)

TABLE 6 PER CAPITA CONSUMPTION OF DAIRY PRODUCTS IN AUSTRALIA

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS


Companies

1. JOHNSON AND JOHNSON

2. ZERIA PHARMACEUTICAL

3. AMAG PHARMACEUTICALS

4. SANOFI

5. BRUNO FARMACEUTICI S.P.A.

6. ROCHE DIAGNOSTICS CORPORATION

7. ROYAL DSM N.V.

8. SHIRE

9. CIPLA

10. ULTRAGENYX PHARMACEUTICAL, INC.

11. FERMENTA BIOTECH, LTD.

12. BIOTECH PHARMACAL

13. SUN PHARMACEUTICAL INDUSTRIES, LTD.

14. KERYX BIOPHARMACEUTICALS, INC.

15. FRESENIUS MEDICAL CARE

16. PFIZER, INC.